Abivax S.A. (ABVX) Form 6-K — Jun 29, 2026
Abivax announced positive topline results from Part 2 of its Phase 3 ABTECT maintenance trial evaluating obefazimod in patients with moderate to severe ulcerative colitis. In the refractory population of induction non-responders, continuous treatment with 50 mg obefazimod resulted in a 37.2% clinical remission rate and 61.5% clinical response rate at Week 44. Patients who relapsed during the trial and were re-treated achieved clinical remission rates of 45.0% to 45.5%.
Key figures
- NDA Submission Timeline
- Fourth Quarter 2026
- Clinical Remission Relapsers 25mg To50mg
- 45.5%
- Clinical Remission Relapsers Placebo To50mg
- 45.0%
- Clinical Response Induction Non Responders 50mg
- 61.5%
- Clinical Remission Induction Non Responders 50mg
- 37.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.